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Our immune system has evolved to recognize and eradicate pathogenic microbes. How-
ever, we have a symbiotic relationship with multiple species of bacteria that occupy the
gut and comprise the natural commensal ﬂora or microbiota. The microbiota is critically
important for the breakdown of nutrients, and also assists in preventing colonization by
potentially pathogenic bacteria. In addition, the gut commensal bacteria appear to be criti-
cal for the development of an optimally functioning immune system. Various studies have
shown that individual species of the microbiota can induce very different types of immune
cells (e.g.,Th17 cells, Foxp3+ regulatoryT cells) and responses, suggesting that the compo-
sition of themicrobiota can have an important inﬂuence on the immune response. Although
the microbiota resides in the gut, it appears to have a signiﬁcant impact on the systemic
immune response. Indeed, speciﬁc gut commensal bacteria have been shown to affect
disease development in organs other than the gut, and depending on the species, have
been found to have a wide range of effects on diseases from induction and exacerbation
to inhibition and protection. In this review, we will focus on the role that the gut microbiota
plays in the development and progression of inﬂammatory/autoimmune disease, and we
will also touch upon its role in allergy and cancer.
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INTERACTION BETWEEN THE GUT MICROBIOTA AND THE
IMMUNE SYSTEM
The trillions of commensal microorganisms that constitute the
intestinal microbiota are primarily composed of ﬁve bacterial
phyla, Firmicutes,Bacteroidetes,Actinobacteria,Proteobacteria, and
Fusobacteria. Bacteroidetes and Firmicutes predominate and rep-
resent∼90% of the total gut microbiota (i.e., 25 and 65%, respec-
tively; Rajilic-Stojanovic et al., 2007). However, these proportions
can vary greatly between individuals and even within single indi-
vidual over time. Although commensal bacteria inhabit the entire
gut, greater numbers reside in the distal part of the small intestine
and in the large intestine or colon. Acquisition of the intesti-
nal microbiota occurs in the ﬁrst year of life and is inﬂuenced
by the maternal bacteria obtained during vaginal delivery (Ben-
net and Nord, 1987; Mandar and Mikelsaar, 1996; Penders et al.,
2006), versusCesarean section (Dominguez-Bello et al., 2010), and
breastfeeding (Yoshioka et al., 1983; Balmer and Wharton, 1989;
Harmsen et al., 2000; Hopkins et al., 2005). Early in life the major
shifts in the gut microbiota can be caused by antibiotics, dietary
changes, etc. (Koenig et al., 2011) as opposed to a purely stochastic
model (Palmer et al., 2007). However, there is a lack of large-scale
studies of temporal variation in adults.
The gut microbiota plays a critical role in the breakdown
of indigestible complex plant polysaccharides, and provides
an important layer of defense against invasion by pathogenic
microorganisms. It is also required for proper development of the
immune system, as indicated by the fact that germ-free (GF) mice
have poorly developed lymphoid tissues. GF mice have spleens
with few germinal centers and poorly formed T and B cell zones,
hypoplastic Peyer’s patches, lower numbers of lamina propria
CD4+ cells and IgA-producingplasma cells (Macpherson andHar-
ris, 2004), and aberrant development and maturation of isolated
lymphoid follicles (Bouskra et al., 2008). The lymphoid organs of
GF mice exhibit aberrant development of T and B cell subsets, and
more speciﬁcally, contain CD4+ T cells that are skewed toward
an T helper 2 (Th2) phenotype and produce little, if any, IFNγ
(Mazmanian et al., 2005), and have fewer and smaller germinal
centers (Bauer et al., 1963). There is also evidence that the micro-
biota plays a key role in the induction of IgA (Klaasen et al., 1993b;
Talham et al., 1999) and maintenance of homeostasis of various
T cell populations in the gut, including regulatory T cells (Tregs),
and T helper 1 (Th1) and 17 (Th17) cells (Gaboriau-Routhiau
et al., 2009).
The commensal bacteria that reside in the gut are diverse, and
individual species appear, in some cases, to have distinct and
opposing roles. Some commensal bacteria appear to drive Treg
development preferentially, while others promote Th17 develop-
ment. In a comparative analysis of terminal ileal tissue from mice
maintained in conventional (CV) versus GF housing, tissue from
CV mice exhibited 5- to 10-fold higher IL-10 and Foxp3 mRNA
expression compared to GF mice, suggesting that the microbiota
can drive Foxp3+Treg induction and/or expansion in the intes-
tine (Gaboriau-Routhiau et al., 2009). Furthermore, in the Peyer’s
patches and mesenteric lymph nodes (LN) of naive GF mice, Tregs
were at a decreased frequency, were less effective at suppressing
responder cell proliferation in vitro, and produced lower levels of
IL-10 and TGFβ than naive mice housed under speciﬁc pathogen-
free (SPF) conditions (Ishikawa et al., 2008). The colonization of
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GF mice with Bacteroides fragilis increases the suppressive capac-
ity of Tregs and induces anti-inﬂammatory cytokine production
by Foxp3+ T cells in the gut (Mazmanian et al., 2008). Similarly,
colonization of GF mice with a cocktail of Clostridium strains
increased dramatically the frequency of IL-10-producing Helios−
Tregs (induced Tregs) in the colonic lamina propria (Atarashi
et al., 2011). Numerous studies have also found that Tregs are
induced following gavage with gut commensal bacteria of either
the Lactobacillus or Biﬁdobacterium genus (Di Giacinto et al.,
2005; O’Mahony et al., 2008; Karimi et al., 2009; Livingston et al.,
2010; Zhang et al., 2010). In contrast, Th17 cell responses appear
to be induced by a restricted number of microbial species, e.g.,
segmented ﬁlamentous bacteria (SFB). Candidatus arthromitus,
commonly called SFB, are Gram-positive bacteria of the Firmi-
cutes phylum and most closely related to the Clostridium genus
(Snel et al., 1995). These bacteria colonize the small intestine
and have been shown to stimulate the production of secretory
IgA (Klaasen et al., 1993b; Talham et al., 1999) and to activate
CD8αβ+TCRαβ+ intraepithelial cells in the small intestine (Ume-
saki et al., 1995). The SFB are thought to play a key role in the
maturation of the adaptive mucosal immune response in the gut.
Indeed, SFB colonization of GF mice has been shown to induce
differentiation of primarily IL-17+ T cells (Ivanov et al., 2008,
2009; Gaboriau-Routhiau et al., 2009) and to a far lesser extent,
IFNγ+Th1 and IL-10+Treg cells (Gaboriau-Routhiau et al., 2009).
These data indicate that SFB can promote the development of
intestinal Th17 cells, a population of T cells that is not only impor-
tant for ﬁghting bacterial infection, but is also involved in the
pathogenesis of a number of inﬂammatory and autoimmune dis-
eases. A microbiota favoring SFB could, therefore, have an impact
on the immune response, and consequently, on the development
of Th17-mediated inﬂammatory/autoimmune diseases in the gut
and at distant sites in predisposed individuals. The speciﬁc mech-
anisms that lead to the preferential induction of Tregs versus Th17
cells by various commensal bacteria are currently unknown. How-
ever, DNA derived from commensal bacteria has been shown
to play a major role in intestinal homeostasis through toll-like
receptor 9 (TLR9) engagement, and appears to be involved in con-
trolling the balance between Tregs and effector cells. Indeed, TLR9
deﬁcient (TLR9−/−) mice exhibit increases in intestinal Foxp3+
Tregs, and decreases in IL-17 and IFN-γ production by compar-
ison to wild-type mice (Hall et al., 2008). One could speculate
that speciﬁc commensal species may differentially modulate the T
effector/Treg cell balance via this mechanism, since the ability of
gut commensal bacteria to stimulate TLR9 varies and depends on
the frequency of CG dinucleotides (Dalpke et al., 2006).
The composition of the microbiota can be inﬂuenced by vari-
ous factors, including diet and exposure to antibiotics. Analysis of
the fecal microbiota of humans and 59 other mammalian species
has shown that the gut microbiota of humans living a mod-
ern lifestyle is typical of omnivorous primates (Ley et al., 2008).
Moreover, feeding GF mice colonized with human fecal micro-
bial communities a high-fat, high sugar “Western” diet instead
of a low-fat, plant polysaccharide-rich diet signiﬁcantly altered
the microbiota composition, resulting in an increase in Firmicutes
and decrease in Bacteroidetes (Turnbaugh et al., 2009). In con-
trast, a diet very high in ﬁber has been associated with increases
in Bacteroidetes and a much lower abundance of Firmicutes in
humans (De Filippo et al., 2010), although other factors may
confound these comparisons. Interestingly,ﬂuctuations in thepro-
portions of these types of commensal bacteria have been found
in patients and animals with inﬂammatory/autoimmune diseases
(see below). In addition, antibiotic treatment is usually followed
by a decrease in the diversity of the microbiota. Although the
composition of the microbiota is similar in the days or weeks
following the termination of treatment, some bacterial members
are lost from the community indeﬁnitely (Jernberg et al., 2007;
Jakobsson et al., 2010). Furthermore, different types of antibiotics
differentially affect bacteria and, consequently, immune cell devel-
opment. Antibiotic treatment (ampicillin, gentamicin, metron-
idazole, neomycin, and vancomycin) that reduced bacteria from
the Firmicutes phylum while increasing the proportion of bacteria
from the Bacteroidetes, phylum was associated with a reduction
in mucosal CD4+T cells expressing IFNγ and IL-17 (Hill et al.,
2010). Similarly, vancomycin or ampicillin treatment, both of
which inhibit Gram-positive bacteria, dramatically decreased the
numbers of Th17 cells in the lamina propria. In contrast, metron-
idazole or neomycin, which target anaerobes and Gram-negative
bacteria, had little effect on the Th17 cell population (Ivanov et al.,
2008). Because the microbiota profoundly affects immune system
development and maturation, it is not surprising that modula-
tion of the balance between the various commensal bacteria can
inﬂuence inﬂammatory/autoimmunedisease development and/or
progression.
INVOLVEMENT OF COMMENSAL BACTERIA IN PROTECTION
AGAINST AUTOIMMUNITY
The less than 100% concordance rate for autoimmune diseases
in monozygotic twins (e.g., <40% for type 1 diabetes; Hyttinen
et al., 2003), suggests that environmental factors can have a strong
inﬂuence on inﬂammatory/autoimmune disease development.
The composition of the microbial community that comprises
the microbiota varies between individuals including monozygotic
twins. Because the gut commensal bacteria inﬂuences the devel-
opment of the immune system, the microbiota could be one of
the environmental factors that affects inﬂammatory/autoimmune
disease development in genetically susceptible individuals, i.e., dif-
ferences in its composition could contribute to the lower than
expected concordance rate in monozygotic twins. The composi-
tion of the gut microbiota may, therefore, either confer protection
or trigger disease in genetically susceptible individuals.
Considerable evidence indicates that the composition of the
microbiota can inﬂuence the development of intestinal inﬂamma-
tion. Some commensal bacteria may induce intestinal inﬂamma-
tionwhile others control it. The commensals capable of controlling
inﬂammation in the gut mediate their effect either by balanc-
ing the immune response in favor of regulation or by controlling
bacteria that may directly mediate intestinal inﬂammation. With
regard to balancing the immune response, commensal bacteria
from the Bacteroidetes and Firmicutes phyla appear to induce
Tregs that can control Th17 cells that are responsible for intesti-
nal inﬂammation. In a recent report, colonization of GF mice
with the human commensal, B. fragilis, was shown to induce IL-
10 production and Foxp3 expression, decrease Th17 cells and
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prevent colitis development. Furthermore, injection of polysac-
charide A (PSA) isolated from B. fragilis was found to recapitulate
the effects of colonization with B. fragilis (Mazmanian et al.,
2008; Round and Mazmanian, 2009), with PSA-induced signaling
through TLR2 expressed by Tregs promoting tolerance (Round
et al., 2011). In addition, mice orally inoculated with murine
Clostridium species belonging to clusters IV and XIVa (Firmicutes
phylum) were resistant to colitis development and exhibited an
increase in the frequency of colonic Tregs (Atarashi et al., 2011).
Various human Lactobacillus strains (of the Firmicutes phylum)
have also been shown to be protective in several animal mod-
els of colitis, including the TNBS-induced and IL-10 deﬁcient
mouse models of colitis, and were found to mediate their effect
via induction of Tregs (Di Giacinto et al., 2005; O’Mahony et al.,
2008; Livingston et al., 2010). Commensal bacteria can also affect
other potentially pathogenic bacteria; for example, commensal
bacteria from the Actinobacteria phylum appear to control the
levels of other commensal bacteria that cause intestinal inﬂam-
mation. Administration of Biﬁdobacterium animalis subsp. Lactis
(Actinobacteria phylum) reduced intestinal inﬂammation in the
T-bet−/−Rag2−/− model of colitis. This was associated with a con-
comitant reduction in Enterobacteriaceae levels, the commensal
bacteria shown to initiate intestinal inﬂammation in this colitis
model. Moreover, the authors reported that the fecal levels of
Biﬁdobacterium in untreated T-bet−/−Rag2−/− mice were lower
compared to control mice, and found that the Biﬁdobacterium
fecal levels were inversely related to the colitis score (Veiga
et al., 2010). Taken together, these studies demonstrate that sev-
eral different species of commensal bacteria can control inﬂam-
mation in the gut via different mechanisms, e.g., by directly
regulating the immune response or by affecting the composi-
tion of the microbiota and reducing other disease-mediating
commensals.
Commensal bacteria can also have a protective effect at sites dis-
tant from the gut. The results of one recent study suggest that the
microbiota plays an important role in type 1 diabetes in genetically
susceptible mice. Type 1 diabetes-susceptible NOD mice that were
crossed with MyD88−/− mice (NODMyD88−/−) were found to be
protected from type 1diabetes. This protection appeared to involve
changes in the composition of themicrobiota, since protectionwas
abrogated when NODMyD88−/− mice were treated with antibi-
otics or derived and maintained under GF conditions. A com-
parison of the gut microbiota between NODMyD88 sufﬁcient and
NODMyD88−/− mice conﬁrmed that there were differences in the
microbiota compositionwhich could account for the differences in
disease susceptibility. The NODMyD88−/− mice had a lower Fir-
micutes/Bacteroidetes ratio than the NODMyD88 sufﬁcient mice,
and an enrichment in cecal Lactobacillacae, Rikenellaceae, and
Porphyromonadaceae. Finally,wild-typeNODmice thatwere colo-
nized at birth with microbiota from NODMyD88−/− mice exhib-
ited signiﬁcantly reduced islet inﬁltration compared to untreated
NOD mice (Wen et al., 2008), i.e., the microbiota from the
NODMyD88−/− mice conferred some protection from diabetes to
wild-type NOD mice. Moreover, a recent publication has reported
that female NOD mice colonized with SFB exhibited a large Th17
population in the lamina propria of the small intestine and were
protected from developing type 1 diabetes (Kriegel et al., 2011).
These ﬁndings corroborate studies showing that Th17 cells do not
directlymediate type 1 diabetes inNODmice (Bending et al., 2009;
Martin-Orozco et al., 2009), and in fact, appear to act as regulatory
cells that protect against disease development (Han et al., 2010;
Nikoopour et al., 2010). Interestingly, a recent studyhas shown that
Th17 cell pathogenicity can be controlled in the small intestine,
where pro-inﬂammatory Th17 cells can acquire a regulatory phe-
notype (rTh17) that includes in vivo immunosuppressive proper-
ties (Esplugues et al., 2011). Taken together, these data suggest that
gutmicrobiota has a signiﬁcant, if complex, inﬂuence on the devel-
opmentof inﬂammatory/autoimmunediseases.Another studyhas
found that the microbiota plays a protective role in a model of
collagen-induced arthritis. The study found that rats maintained
in a GF environment developed more severe rheumatoid arthritis
(RA) than rats maintained in a conventional environment, sug-
gesting that themicrobiota had a suppressive effect onRAdevelop-
ment (Breban et al., 1993). Lastly, a series of studies has shown that
the microbiota can protect against central nervous system (CNS)
disease. Oral administration of antibiotic, leading to a reduction
in bacteria from the Firmicutes phylum, but a relative increase in
bacteria from theBacteroidetes phylum, impaired the development
of myelin oligodendrocyte glycoprotein (MOG) or proteolipid
protein-induced experimental autoimmune encephalitis (EAE) in
mice. In this study, protectionwas associatedwith diminished pro-
inﬂammatory responses, higher numbers of Tregs in mesenteric
LN and potent IL-10-producing Foxp3+ Tregs that were present
in the LN (Ochoa-Reparaz et al., 2009, 2010). Moreover, oral
administration of PSA isolated fromB. fragilis (of theBacteroidetes
phylum) was able to prevent EAE development via enhancement
of CD103+ DC that converted naïve T cells into IL-10-producing
Foxp3+ Tregs, suggesting that antibiotic-mediated protection is
mediated the increase inBacteroidetes (Ochoa-Reparaz et al., 2009,
2010). Finally,oral administration of probiotics, including the Lac-
tobacillus and Biﬁdobacterium species, has been shown to protect
against development of various autoimmune diseases such as type
1 diabetes (Matsuzaki et al., 1997; Calcinaro et al., 2005), exper-
imental autoimmune encephalomyelitis (Lavasani et al., 2010),
experimental RA (Kato et al., 1998; Baharav et al., 2004; So et al.,
2008), and systemic lupus erythematosus (personal observation;
Alard et al., 2009), via induction of IL-10-producing Tregs and
attenuation of Th1 and Th17 cytokines. It is not clear whether
the Tregs are induced upon direct interaction with the probi-
otics and/or via stimulation with tolerogenic antigen presenting
cells that have been induced by the probiotics. We have, however,
shown recently that dendritic cells culturedwithLactobacillus casei
shift their cytokine proﬁle in favor of IL-10, and are able to pre-
vent type 1 diabetes development upon injection into NOD mice.
Since a single injection of L. casei-treated DC is sufﬁcient to medi-
ate long-term protection, the mechanism in this case most likely
involves induction of regulatory cells (Manirarora et al., 2011).
Altogether, these data emphasize the importance of a balanced gut
microbiota that can induce a protective immune response capable
of suppressing inﬂammation in organs distant from the gut, via
induction of tolerogenicDCandTregs.How these cells trafﬁc from
the gut to the distal lymph nodes and possibly to the peripheral
tissue (CNS, joint, pancreas) is currently unknown and remains to
be determined.
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Studies have indicated that the composition of the microbiota
can have a signiﬁcant effect on the development of inﬂamma-
tory/autoimmune disease in humans. The composition of the gut
microbiota differs greatly in subsets of patients with inﬂamma-
tory bowel disease (IBD), including Crohn’s disease and ulcerative
colitis, compared to non-IBD individuals. The microbiota of IBD
patients is characterized by depletion of Bacteroidetes and Firmi-
cutes (Frank et al., 2007). More speciﬁcally, recurrence of Crohn’s
disease was associated with decreases in the relative proportion of
Faecalibacterium prausnitzii, a bacteriumbelonging toClostridium
cluster IV, in these patients (Sokol et al., 2009). In animal studies,
F. prausnitzii has been shown to have anti-inﬂammatory effects,
and oral administration of F. prausnitzii has been found to reduce
the severity of TNBS-induced colitis (Sokol et al., 2008). These data
suggest that restoration of the microbial balance in IBD patients
may be a good strategy to treat this disease, and in fact, administra-
tion of VSL#3, a cocktail of several Lactobacillus species (L. Casei,
Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacil-
lus delbrueckii), Biﬁdobacterium species (Biﬁdobacterium longum,
Biﬁdobacterium breve, and Biﬁdobacterium infantis) and a Strepto-
coccus salivarius subsp.,Thermophilus, has been shown to decrease
ulcerative colitis in patients with mild to moderately active ulcera-
tive colitis (Sood et al., 2009; Tursi et al., 2010). Studies in patients
with early RA have also found that Biﬁdobacteria and B. fragilis
in the gut are decreased (Vaahtovuo et al., 2008), suggesting that
alteration in the abundance of these two commensal species may
inﬂuence the pathogenesis of RA. However, in patients with estab-
lished disease, the possibility that an alteration in the composition
of the microbiota may be a consequence rather than a cause of the
disease cannot be ruled out.
In conclusion, commensal bacteria belonging to the Biﬁdobac-
terium,Bacteroides,Clostridium, and Lactobacillus genera are asso-
ciated with inﬂammatory/autoimmune disease protection. There-
fore, establishing a balancedmicrobiota in favor of these protective
commensal bacteria may be a good strategy for the preven-
tion and/or treatment of inﬂammatory/autoimmune diseases in
autoimmune-prone individuals.
INVOLVEMENT OF COMMENSAL BACTERIA IN TRIGGERING
INFLAMMATORY/AUTOIMMUNE DISEASE
Microbial pathogens have long been implicated in the etiology of
a variety of autoimmune/inﬂammatory diseases, including IBD
(Sanderson and Hermon-Taylor, 1992; Chen et al., 2000), RA
(Toivanen, 2003), experimental autoimmune encephalomyelitis
(Cermelli and Jacobson, 2000; Buljevac et al., 2005; Gilden, 2005;
Farrell et al., 2009), type 1 diabetes (Filippi and vonHerrath, 2005),
and systemic lupus erythematosus (Cavallo and Granholm, 1990;
Zandman-Goddard and Shoenfeld, 2005; Poole et al., 2006). How-
ever, a growing body of evidence suggests that speciﬁc commensal
bacteria may also negatively impact inﬂammatory and autoim-
mune diseases in genetically susceptible individuals. Interestingly,
rendering mice germ-free (GF) can dramatically alter inﬂamma-
tory/autoimmune disease incidence and severity, and/or the kinet-
ics of disease onset and progression in animal models of disease.
This is not surprising since we know that commensal bacteria play
an important role in shaping the host systemic immune response.
However, the mechanisms underlying the relationship between
commensal microorganisms and the induction/exacerbation of
autoimmune/inﬂammatory diseases are poorly understood. Fur-
thermore, it is unclear how individual microbial species compris-
ing the microbiota contribute to the effects on these diseases.
Recent studies focusing on the relationship between the micro-
biota and induction of autoimmunity have begun to shed some
light on these issues.
Most mouse models of colitis are antibiotic-responsive, and
patients with IBD often beneﬁt from treatment with antibi-
otics, suggesting that bacteria play a role in disease pathogenesis.
The general consensus is that IBD may be driven by aberrant
pro-inﬂammatory host responses to the commensal microbiota
(Packey and Sartor,2008).A recent studyhas found that themicro-
biota can induce inﬂammation in models of colitis by activating
T cells via both innate and adaptive immune mechanisms (Feng
et al., 2010). In that study, homeostatic proliferation of transferred
T cells was inhibited in GF RAG−/− mice, but restored after recon-
stitution with Altered Schaedler’s Flora (a standardized cocktail
of mouse microbiota), indicating that T cells require the presence
of the microbiota to proliferate. Moreover, microbiota-induced
production of IL-6 by DC was required to reach the threshold
number of IFNγ and IL-17-producing microbiota-speciﬁc T cells
(i.e., induction of T cell proliferation) that was needed to induce
colitis (Feng et al., 2010). In other studies, a number of bac-
terial species isolated from the intestines of IBD patients have
been shown to be capable of inducing intestinal inﬂammation in
rodents, including Helicobacter hepaticus, enterotoxigenic B. frag-
ilis, and Bacteroides vulgatus. H. hepaticus infection is associated
with the spontaneous development of colitis in some types of
immunodeﬁcient, but not immunocompetent mice (Ward et al.,
1996). Furthermore, colonizationwith enterotoxigenic strains, but
not non-toxigenic strains, of B. fragilis have been shown to induce
colitis. Enterotoxigenic B. fragilis of human origin mediates col-
itis in multiple intestinal neoplasia (Min) transgenic mice in a
Th17 cell-dependent manner (Wu et al., 2009). Similarly, entero-
toxigenic B. fragilis of piglet origin has been shown to enhance
DSS-induced colitis in mice (Rabizadeh et al., 2007), and the B.
fragilis toxin appears to be essential for disease pathogenesis (Rhee
et al., 2009). In an older study, colitis severity was found to be
increased in a carrageenan-based model of colitis in guinea pigs
after oral administration of B. vulgatus isolated from IBD patients,
but not healthy individuals. This disease exacerbation could be
transferred to recipients via spleen cells (Onderdonk et al., 1984),
suggesting that bacteria isolated from IBD patients were induc-
ing a cell-mediated (most likely T cell) immune response capable
of enhancing inﬂammation. Interestingly, another study has found
that a single species of commensal bacteria,ﬁlamentous segmented
bacteria (SFB), can induce intestinal inﬂammation in the presence
of a limited microbiota (Stepankova et al., 2007). In this study,
GF SCID mice were colonized with individual or combinations
of strains of anaerobic and aerobic bacteria and SFB, including
Enterococcus faecalis, SFB, Fusobacterium mortiferum, Bacteroides
distasonis,F.mortiferum + SFB,B. distasonis + SFB, and a SPFbac-
terial cocktail with limited diversity (SPF cocktail) ±SFB. Using
the CD45high transfer model of intestinal inﬂammation, the study
found that only the mice colonized with the SPF cocktail +SFB
developed clinical andhistological signs of intestinal inﬂammation
Frontiers in Microbiology | Cellular and Infection Microbiology September 2011 | Volume 2 | Article 180 | 4
Kosiewicz et al. Gut microbiota and diseases
following transfer of CD45RBhigh cells (Stepankova et al., 2007).
These data indicate that, unlike SFB, most gut bacteria cannot or
do not trigger intestinal inﬂammation in the presence of a limited
microbiota, such as the typical SPF bacteria.
The involvement of SFB in inﬂammatory disease pathogenesis
is not limited to the intestine. Two recent studies have shown that
SFB may also be involved in development of experimental autoim-
mune encephalomyelitis (EAE) (Lee et al., 2011) and rheumatoid
arthritis (RA) (Wu et al., 2010). In the ﬁrst study, the authors
found that GF mice exhibited decreased severity of MOG-induced
EAE compared to mice raised under SPF conditions. The reduced
severity was associated with reduced IL-17A and IFNγ production
andRORγt transcripts,but elevated levels of CD4+CD25+Foxp3+
cells. Interestingly, whereas transfer of CD4+ T cells from MOG-
immunized GF mice into RAG−/− GF mice only induced very
mild EAE, transfer of CD4+ T cells from MOG-immunized stan-
dard pathogen free (SPF) mice induced severe disease, suggesting
that the gut microbiota plays a role in activating T cells capable
of inducing EAE. Finally, intestinal colonization of GF mice with
SFB alone restored susceptibility to severe EAE induction, and cor-
related with elevated IL-17 and IFNγ expression in T cells in the
spinal cord and small intestine lamina propria as well as a reduc-
tion of Foxp3+ Tcell levels. This study demonstrates that intestinal
colonization with SFB can induce Th17 cells that attack the cen-
tral nervous system (CNS) (Lee et al., 2011). In the second study,
arthritis-prone K/BxN mice raised under GF conditions exhib-
ited attenuated RA that was associated with a reduction in serum
autoantibody titers, splenic autoantibody-secreting cells, germinal
centers, and IL-17. Interleukin-17 was found to be critical for the
pathogenesis of the disease in these mice, as treatment with anti-
IL-17 antibodies abrogated RA development in mice raised under
SPF conditions. Interestingly, colonization of GFK/BxNmicewith
a single bacterial species, SFB, resulted in the rapid development
of arthritis, which correlated with restoration of IL-17-producing
T cells in the lamina propria. These cells could in turn migrate to
the spleen where they provided help for germinal center forma-
tion and antibody production (Wu et al., 2010). Therefore, SFB,
a bacterium known to induce IL-17 production (Ivanov et al.,
2009), is capable of triggering RA in arthritis-prone K/BxN mice
via activation of Th17 cells (Wu et al., 2010). Colitis, EAE, and
RA are all mediated by IL-17-producing cells, and it is perhaps
not surprising that a commensal bacteria that induces Th17 cells
may be involved in the etiology of these diseases. However, it is
surprising that a commensal gut bacteria (such as SFB) can play a
role in the development of autoimmune disease at a distant site,
i.e., CNS (Lee et al., 2011) or joints (Wu et al., 2010). In fact, evi-
dence of SFB-induced Th17 cells could be found not only in the
intestine, but also in the spinal chord and spleen, demonstrating
that a single intestinal commensal bacterial species is capable of
priming immune responses that are extra-intestinal and extend to
peripheral lymphoid organs and tissues. However, the role that the
intestinal SFB-inducedTh17 cells play at the disease sites, i.e., in the
spinal chord or the joints, remains to be determined. Several stud-
ies have shown that the presence of IL-17 in the joints enhanced
disease (Lubberts et al., 2004; Jacobs et al., 2009), suggesting that
Th17 cells could amplify the inﬂammatory process in the joints.
Indeed, IL-17 receptor is expressed by awide range of synovial cells
(Yao et al., 1995; Silva et al., 2003), and IL-17 drives these cells to
produce pro-inﬂammatory mediators such as cytokines (GM-
CSF) and chemokines (CXCL2, CXCL8), and induces recruitment
of neutrophils (Laan et al., 1999, 2003). Moreover, one could spec-
ulate that Th17 cells may also participate in the inﬂammatory
process by producing other cytokines capable of promoting the
inﬂammatory response. For instance, IL-23 and GM-CSF have
been shown very recently to play a crucial role in EAE induc-
tion. Interleukin-23 appears to induce Th17 or RORγt+ T cells to
produce GM-CSF that is required for disease induction; this was
demonstrated in experiments showing that GM-CSF-producing
IL-17-deﬁcient T cells, but not GM-CSF-deﬁcient Th17 cells, were
able to induce EAE (Codarri et al., 2011; El-Behi et al., 2011).
Furthermore, GM-CSF seems to target the myeloid cells that are
responsible for sustaining inﬂammation in the CNS (El-Behi et al.,
2011). Depending on the type of autoimmune diseases or the
site of inﬂammation, SFB-induced Th17 cells may therefore pro-
mote/exacerbate inﬂammation in tissue through the production
of GM-CSF and/or IL-17.
Understanding the role that commensal bacteria play in dis-
ease development in humans has been challenging. Studies about
the composition of the gut microbiota in patients have identi-
ﬁed bacteria with the potential to cause disease. Nonetheless, it
is also possible that these microorganisms colonize the gut after
disease is established and are not involved in the development
of the disease. There is, however, a general consensus that IBD
arises from an abnormal immune response to bacterial com-
ponents of the intestinal microbiota (Packey and Sartor, 2008).
Indeed, it has been reported that a subset of people with Crohn’s
disease harbor a strain of adherent–invasive Escherichia coli in
their small intestine that is potentially pro-inﬂammatory (Pine-
ton de Chambrun et al., 2008). In addition, RA patients treated
with antibiotics such as minocycline exhibit signiﬁcant disease
improvement (Stone et al., 2003), suggesting that the commen-
sal bacteria contributes, at some level, to disease development.
Although it has been shown that humans can be colonized with
SFB (Klaasen et al., 1993a), there is little evidence yet for involve-
ment of SFB in inﬂammatory/autoimmune diseases in humans.
It would be of great interest to determine whether SFB is more
prominent in the microbiota of patients exhibiting certain types
of autoimmune diseases, i.e., Th17-mediated. Moreover, multiple
issues remain to be addressed concerning the involvement of SFB
in autoimmune diseases, including identifying the molecules that
mediate Th17 cell induction as well as determining whether other
Th17-mediated autoimmune diseases can be triggered by SFB.
ROLE OF THE MICROBIOTA IN ALLERGIC DISEASES
In addition to inﬂammatory and autoimmune diseases, there are
other chronic diseases that may be impacted by the gut micro-
bial community. In particular, allergic disease development has
been associated with alterations in the intestinal microbiota. The
incidence of allergic diseases has increased over the past 40 years
in industrialized countries including the United States, Canada,
United Kingdom, Ireland, New Zealand, and Australia, but not
in developing countries. These data suggest that environmental
changes are a major factor in the development of allergic dis-
eases (Asher, 1998; Mannino et al., 1998; Beasley et al., 2000).
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The “hygiene hypothesis” suggests that the increase in the preva-
lence of allergic diseases observed in developed countries could
be due to decreased early exposure to infectious agents that may
alter the immune response and, in particular, the immunoregula-
tory compartment (Okada et al., 2010). However, the “microﬂora
hypothesis” has been put forth as an alternative explanation and
is based on changes in the intestinal microbiota that are due
to antibiotic use and dietary differences (Noverr and Huffnagle,
2005). In either case, the regulatory mechanisms that normally
control the Th2 responses generally associated with allergic dis-
eases and asthma would not develop properly. Indeed, treatment
of normal 3-week-old mice with the broad-spectrum antibiotic,
kanamycin, results in the elimination of all Gram-negative bacte-
ria in the stool, and a subsequent shift to a Th2 response (Oyama
et al., 2001), suggesting that intestinal bacteria are involved in
controlling the Th2 response. This was further supported in a
study showing that treatment of mice with antibiotics combined
with oral administration of the commensal fungus, Candida albi-
cans, triggers pulmonary allergic responses (Noverr et al., 2004).
Taken together, these studies suggest that the microbiota plays an
important role in controlling allergic diseases.
Several studies have reported differences in the composition of
the microbiota of infants who develop allergic diseases. Infants
with food allergies were found to exhibit an imbalance between
“beneﬁcial” and potentially harmful bacteria, i.e., Lactobacilli and
Biﬁdobacteria species were lower while coliforms and Staphylococ-
cus aureus were higher (Bjorksten et al., 1999). Decreased levels
of Biﬁdobacteria were also observed in infants with atopic eczema
(Kirjavainen et al., 2001). Moreover, Biﬁdobacteria and Entero-
coccus were decreased while Clostridium was increased, resulting
in a reduced ratio of Biﬁdobacteria to Clostridia in infants that
developed atopic dermatitis (Bjorksten et al., 2001). These data
suggest that speciﬁc species of intestinal commensal bacteria can
play either a pathogenic or protective role in allergies that occur
in the gut or at sites distant from the gut, such as lung and skin.
Prophylactic approaches based on the administration of probi-
otics to newborns at high risk for allergies have proven successful.
The World Health Organization has deﬁned probiotics as “live
microorganisms which when administered in adequate amounts
confer a health beneﬁt on the host” FAO/WHO (2002). Admin-
istration of L. casei GG to the mothers before and after (via
breastfeeding) delivery prevents atopic eczema, as well as other
atopic diseases that develop later, in children at risk (Kalliomaki
et al., 2001, 2003). Protection from allergic diseases provided by
oral administration of non-pathogenic E. coli in early life was
shown to extend to adult life (Lodinova-Zadnikova et al., 2003).
Finally, a number of studies have been performed using probiotics
to treat pre-existing atopic disease in infants. These studies found
that administration of Lactobacilli was able to decrease the severity
of various allergic diseases, including atopic eczema, atopic der-
matitis, and food allergy in these children (Majamaa and Isolauri,
1997; Kirjavainen et al., 1999; Rosenfeldt et al., 2003; Viljanen
et al., 2005). There is no evidence to date indicating that probiotic
therapies have a beneﬁcial effect on the incidence or severity of
asthma in children at high risk (Vliagoftis et al., 2008). However,
studies using animal models have found that oral administration
of certain Lactobacilli and Biﬁdobacterium species were able to
modulate allergic responses in the respiratory tract apparently via
induction of regulatoryT cells, suggesting that itmay be possible to
treat asthma using an optimal combination of probiotics (Feleszko
et al., 2007; Forsythe et al., 2007; Karimi et al., 2009; Lyons et al.,
2010).
As described above for autoimmune diseases, microbiota that
favor certain species of commensal bacteria appears to also predis-
pose or protect susceptible individuals to allergy development at
various extra-intestinal sites, including lung and skin. The mecha-
nisms by which intestinal immune responses affect inﬂammatory
responses at distant sites are still unknown and remain to be
established.
ROLE OF THE MICROBIOTA IN CANCER
The intestinal microbiota does not only inﬂuence autoimmune
and allergic diseases, but has also been implicated in the devel-
opment of cancer, especially colon cancer. Colorectal cancer is
highly prevalent in the United States, with an estimated 1 in
20 men and women receiving a diagnosis of colon or rectum
cancer sometime during their lifetime (National Cancer Insti-
tute Website: http://seer.cancer.gov/statfacts/html/colorect.html).
Similarly, colorectal cancer is the second and third most common
cancer in women and men, respectively, in European Union coun-
tries (Ferlay et al., 2007). This is an important heath problem in
developed countries, where the primary risk factor is diet in up to
80% of all colorectal cancers (Bingham, 2000).
Interestingly, accumulating evidence in the last 3 years has
underscored the importance of the intestinal microbiota in the
development of colorectal cancer (Bingham, 2000; Davis and Mil-
ner, 2009; O’Keefe et al., 2009; Uronis et al., 2009). In fact, diet
and the composition of the microbiota strongly correlate with the
risk of developing colorectal cancer in certain groups of individu-
als (Bingham, 2000; Davis and Milner, 2009; O’Keefe et al., 2009).
One mechanism by which commensal bacteria contribute to the
initiation of colorectal cancer involves the induction of inﬂam-
mation by commensal bacteria. A study using an animal model
of colorectal carcinoma, IL-10−/− mice exposed to the carcino-
gen, azoxymethane (AOM) tested this hypothesis. In this study,
AOM-exposed IL-10−/− mice developed colorectal carcinomas
when housed conventionally, but not when housed under GF con-
ditions. Furthermore, MyD88 (an adaptor molecule necessary for
most TLR signaling) was found to be essential in this process, sug-
gesting that bacterial-induced inﬂammation in the intestine can
play a crucial role in the development of the carcinomas (Uro-
nis et al., 2009). Interestingly, ingestion of lactic acid-producing
bacteria has been shown to prevent carcinogen-induced lesions
and tumors in animal models (Goldin and Gorbach, 1980; Goldin
et al., 1996; Pool-Zobel et al., 1996; Challa et al., 1997; Rowland
et al., 1998). However, the epidemiologic studies are controversial
in humans; some studies have found no association (Kampman
et al., 1994a,b; Kearney et al., 1996), whereas others have found a
signiﬁcant association (Malhotra, 1977; Peters et al., 1992; Boutron
et al., 1996) between consumption of fermentedmilk products and
occurrence of colon cancer. Further studies are, therefore, needed
to determine if probiotics can be used as protective agents for the
prevention of human colon cancer.
Unlike the situation in autoimmune and allergic diseases,
there is little evidence that the microbiota directly affects the
immune response against tumors, and consequently, somehow
Frontiers in Microbiology | Cellular and Infection Microbiology September 2011 | Volume 2 | Article 180 | 6
Kosiewicz et al. Gut microbiota and diseases
impacts tumor progression. One can, however, speculate that
the type of immune response generated by the gut commen-
sal bacteria could potentially inﬂuence tumor immunity. For
example, mice colonized with enterotoxigenic B. fragilis exhibit
colonic Th17 inﬂammatory inﬁltrates that are involved in induc-
tion of colon tumors, as indicated by inhibition of colon tumor
formation following treatment with anti-IL-17 antibody (Wu
et al., 2009). Moreover, Th17 cells have been found in cellular
inﬁltrations in a variety of tumors, including prostate (Sfanos
et al., 2008), pancreatic (Gnerlich et al., 2010), and ovarian
cancer (Kryczek et al., 2009a), and in stomach cancer and the
lymph nodes draining gastric cancer sites (Zhang et al., 2008).
The frequency of Th17 cells correlates with the clinical stage
of gastric cancer, i.e., Th17 cells are found at higher levels in
late stage versus early stage (Zhang et al., 2008). On the other
hand, Th17 cells appear to have a beneﬁcial role in human
ovarian cancer (Kryczek et al., 2009a) and murine melanoma,
pancreatic, and colon cancer (Muranski et al., 2008; Kryczek
et al., 2009b; Gnerlich et al., 2010). It is, therefore, possible
that a microbiota favoring commensal bacteria that induces a
Th17 response could have differential effects on tumors depend-
ing on the type of tumor or the stage of tumor develop-
ment, and as found for autoimmunity and allergy, could alter
the immune response to tumors at extra-intestinal as well as
intestinal sites.
CONCLUSION
Genetic and environmental factors appear to shape the compo-
sition of the gut microbiota, which in turn plays a very impor-
tant role in shaping the immune response at both intestinal and
extra-intestinal sites, and in controlling the development of some
types of autoimmune and allergic diseases as well as some forms
of cancer. Therefore, any external factor that can alter the gut
microbiota balance, such as diet or antibiotic treatment, should be
viewed as a potential risk factor for development of these inﬂam-
matory diseases. Any alteration of the microbiota that leads to
(1) a reduction in commensal bacteria favoring regulatory cells
(Foxp3+ or other, e.g., rTh17) or (2) an enrichment in commen-
sal bacteria favoring the induction of potential pathogenic cells
may elicit disease in genetically susceptible individuals (Figure 1).
However, the relationship between gut microbiota, immunity, and
disease is very complex, since the same commensal bacteria can
induce a protective response or a pathogenic response depending
on the susceptibility of the individual. SFB is the perfect exam-
ple, since it is protective in type 1 diabetes, but causes disease
in mouse models of EAE or arthritis. The speciﬁc commensal
microorganisms that contribute to either the etiology of or pro-
tection from many different types of diseases have not yet been
fully identiﬁed and described. Future studies aimed at determin-
ing the impact of speciﬁc commensal bacteria on the immune
response and induction of inﬂammatory diseases are crucial for
a better understanding of pathogenesis of these diseases. Further-
more, an understanding of the genetic and environmental factors
that shape the composition of themicrobiota will provide the basis
for strategies that will allow for the manipulation of microbiota in
individuals at risk of developing disease. With this information in
hand, it should be possible to design novel tailored therapies capa-
ble of preventing disease development in high risk individuals and
treating established disease in already sick patients. Although not
discussed in this review, other microorganisms, such as fungi and
FIGURE 1 | Impact of the composition of the flora on the immune
response and disease development. Dysbiosis can arise from either (1) a
reduction in Treg-inducing bacteria (e.g., Biﬁdobacteria or Bacteroides) that
results in decreasedTregs, but unchanged levels of Teff cells; or (2) an
enrichment in pro-inﬂammatory bacteria (e.g., SFB) that results in increased
Teff cells, but unchanged levels of Tregs. In both cases, theTreg:Teff cell
balance is biased toward theTeff cells, and the outcome of this imbalance can
be development of disease in genetically susceptible individuals.
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viruses, are present in the intestine, and have also been shown to be
involved in autoimmune disease or allergic disease pathogenesis in
susceptible animals (Noverr et al., 2004; Cadwell et al., 2010). It
would, therefore, be very important in the future to extend the
studies cited above to these microorganisms rather than limiting
them to commensal bacteria only. It may eventually be possible
to establish proﬁles of the microbiota in humans based on the
bacterial species composition or enterotypes (Arumugam et al.,
2011). This “biological ﬁngerprint” of the future, similar to blood
or tissue typing, may be used to predict responses to drugs or diet
as well as aid in disease diagnosis/prognosis, and could ultimately
lead to the development of personalized therapies.
REFERENCES
Alard, P., Parnell, S. A., Manirarora, J.
N., and Kosiewicz, M. M. (2009).
Probiotics control lupus progression
via induction of regulatory cells and
IL-10 production. J. Immunol. 182,
50.30.
Arumugam, M., Raes, J., Pelletier, E.,
Le Paslier, D., Yamada, T., Mende,
D. R., Fernandes, G. R., Tap, J.,
Bruls, T., Batto, J. M., Bertalan, M.,
Borruel, N., Casellas, F., Fernandez,
L., Gautier, L., Hansen, T., Hattori,
M., Hayashi, T., Kleerebezem, M.,
Kurokawa, K., Leclerc, M., Levenez,
F., Manichanh, C., Nielsen, H. B.,
Nielsen, T., Pons, N., Poulain, J.,
Qin, J., Sicheritz-Ponten, T., Tims,
S., Torrents, D., Ugarte, E., Zoe-
tendal, E. G., Wang, J., Guarner,
F., Pedersen, O., De Vos, W. M.,
Brunak, S., Dore, J., Consortium,
M., Weissenbach, J., Ehrlich, S. D.,
Bork, P., Antolin, M., Artiguenave,
F., Blottiere, H. M., Almeida, M.,
Brechot, C., Cara, C., Chervaux, C.,
Cultrone, A., Delorme, C., Denar-
iaz, G., Dervyn, R., Foerstner, K.
U., Friss, C., Van De Guchte, M.,
Guedon, E., Haimet, F., Huber, W.,
Van Hylckama-Vlieg, J., Jamet, A.,
Juste, C., Kaci, G., Knol, J., Lakhdari,
O., Layec, S., Le Roux, K., Maguin,
E., Merieux, A., Melo Minardi, R.,
M’Rini, C., Muller, J., Oozeer, R.,
Parkhill, J., Renault, P., Rescigno, M.,
Sanchez, N., Sunagawa, S., Torrejon,
A., Turner, K., Vandemeulebrouck,
G., Varela, E., Winogradsky, Y., and
Zeller, G. (2011). Enterotypes of the
human gut microbiome. Nature 43,
174–180.
Asher, M. I. (1998). Worldwide varia-
tions in the prevalence of asthma
symptoms: the International Study
of Asthma and Allergies in Child-
hood (ISAAC). Eur. Respir. J. 12,
315–335.
Atarashi, K., Tanoue, T., Shima, T.,
Imaoka, A., Kuwahara, T., Momose,
Y., Cheng, G., Yamasaki, S., Saito, T.,
Ohba, Y., Taniguchi, T., Takeda, K.,
Hori, S., Ivanov, Ii, Umesaki, Y., Itoh,
K., and Honda, K. (2011). Induc-
tion of colonic regulatory T cells
by indigenous Clostridium species.
Science 331, 337–341.
Baharav, E., Mor, F., Halpern, M., and
Weinberger, A. (2004). Lactobacillus
GG bacteria ameliorate arthritis in
Lewis rats. J. Nutr. 134, 1964–1969.
Balmer,S. E., andWharton,B.A. (1989).
Diet and faecal ﬂora in the newborn:
breastmilk and infant formula.Arch.
Dis. Child. 64, 1672–1677.
Bauer, H., Horowitz, R. E., Levenson,
S. M., and Popper, H. (1963). The
response of the lymphatic tissue
to the microbial ﬂora. Studies on
germfree mice. Am. J. Pathol. 42,
471–483.
Beasley, R., Crane, J., Lai, C. K., and
Pearce, N. (2000). Prevalence and
etiology of asthma. J. Allergy Clin.
Immunol. 105, S466–S472.
Bending, D., De La Pena, H., Veld-
hoen, M., Phillips, J. M., Uytten-
hove, C., Stockinger, B., and Cooke,
A. (2009). Highly puriﬁed Th17 cells
from BDC2.5NOD mice convert
into Th1-like cells in NOD/SCID
recipient mice. J. Clin. Invest. 119,
565–572.
Bennet, R., and Nord, C. E. (1987).
Development of the faecal anaer-
obic microﬂora after caesarean
section and treatment with antibi-
otics in newborn infants. Infection
15, 332–336.
Bingham,S.A. (2000).Diet and colorec-
tal cancer prevention. Biochem. Soc.
Trans. 28, 12–16.
Bjorksten, B., Naaber, P., Sepp, E., and
Mikelsaar, M. (1999). The intestinal
microﬂora in allergic Estonian and
Swedish 2-year-old children. Clin.
Exp. Allergy 29, 342–346.
Bjorksten, B., Sepp, E., Julge, K.,
Voor, T., and Mikelsaar, M. (2001).
Allergy development and the intesti-
nal microﬂora during the ﬁrst year
of life. J. Allergy Clin. Immunol. 108,
516–520.
Bouskra, D., Brezillon, C., Berard, M.,
Werts, C., Varona, R., Boneca, I. G.,
and Eberl, G. (2008). Lymphoid tis-
sue genesis induced by commensals
through NOD1 regulates intestinal
homeostasis. Nature 456, 507–510.
Boutron, M. C., Faivre, J., Marteau,
P., Couillault, C., Senesse, P., and
Quipourt,V. (1996). Calcium, phos-
phorus, vitamin D, dairy prod-
ucts and colorectal carcinogenesis: a
French case – control study. Br. J.
Cancer 74, 145–151.
Breban,M. A.,Moreau,M. C., Fournier,
C., Ducluzeau, R., and Kahn, M.
F. (1993). Inﬂuence of the bacterial
ﬂora on collagen-induced arthritis
in susceptible and resistant strains of
rats.Clin. Exp. Rheumatol. 11,61–64.
Buljevac, D.,Van Doornum, G. J., Flach,
H. Z., Groen, J., Osterhaus, A. D.,
Hop, W., Van Doorn, P. A., Van Der
Meche, F. G., and Hintzen, R. Q.
(2005). Epstein-Barr virus and dis-
ease activity in multiple sclerosis.
J. Neurol. Neurosurg. Psychiatr. 76,
1377–1381.
Cadwell, K., Patel, K. K., Maloney, N.
S., Liu, T. C., Ng, A. C., Storer, C.
E., Head, R. D., Xavier, R., Stappen-
beck, T. S., and Virgin, H. W. (2010).
Virus-plus-susceptibility gene inter-
action determines Crohn’s disease
gene Atg16L1 phenotypes in intes-
tine. Cell 141, 1135–1145.
Calcinaro, F., Dionisi, S., Marinaro, M.,
Candeloro, P., Bonato, V., Marzotti,
S., Corneli, R. B., Ferretti, E., Gulino,
A., Grasso, F., De Simone, C., Di
Mario, U., Falorni, A., Boirivant, M.,
and Dotta, F. (2005). Oral probiotic
administration induces interleukin-
10 production and prevents spon-
taneous autoimmune diabetes in
the non-obese diabetic mouse. Dia-
betologia 48, 1565–1575.
Cavallo, T., and Granholm, N. A.
(1990). Lipopolysaccharide from
Gram-negative bacteria enhances
polyclonal B cell activation and exac-
erbates nephritis in MRL/lpr mice.
Clin. Exp. Immunol. 82, 515–521.
Cermelli, C., and Jacobson, S. (2000).
Viruses and multiple sclerosis. Viral
Immunol. 13, 255–267.
Challa, A., Rao, D. R., Chawan, C. B.,
and Shackelford, L. (1997). Biﬁ-
dobacterium longum and lactulose
suppress azoxymethane-induced
colonic aberrant crypt foci in rats.
Carcinogenesis 18, 517–521.
Chen, W., Li, D., Paulus, B., Wilson, I.,
and Chadwick, V. S. (2000). Detec-
tion of Listeria monocytogenes by
polymerase chain reaction in intesti-
nal mucosal biopsies from patients
with inﬂammatory bowel disease
and controls. J. Gastroenterol. Hepa-
tol. 15, 1145–1150.
Codarri, L., Gyulveszi, G., Tosevski,
V., Hesske, L., Fontana, A., Mag-
nenat, L., Suter, T., and Becher, B.
(2011). RORgammat drives produc-
tion of the cytokine GM-CSF in
helper T cells, which is essential for
the effector phase of autoimmune
neuroinﬂammation. Nat. Immunol.
12, 560–567.
Dalpke,A.,Frank, J.,Peter,M.,andHeeg,
K. (2006). Activation of toll-like
receptor 9 by DNA from different
bacterial species. Infect. Immun. 74,
940–946.
Davis, C. D., and Milner, J. A.
(2009). Gastrointestinal microﬂora,
food components and colon can-
cer prevention. J. Nutr. Biochem. 20,
743–752.
De Filippo, C., Cavalieri, D., Di Paola,
M., Ramazzotti, M., Poullet, J. B.,
Massart, S., Collini, S., Pieraccini,
G., and Lionetti, P. (2010). Impact
of diet in shaping gut microbiota
revealed by a comparative study
in children from Europe and rural
Africa. Proc. Natl. Acad. Sci. U.S.A.
107, 14691–14696.
Di Giacinto, C., Marinaro, M., Sanchez,
M., Strober, W., and Boirivant, M.
(2005). Probiotics ameliorate recur-
rent Th1-mediated murine coli-
tis by inducing IL-10 and IL-10-
dependent TGF-beta-bearing reg-
ulatory cells. J. Immunol. 174,
3237–3246.
Dominguez-Bello,M.G.,Costello,E. K.,
Contreras, M., Magris, M., Hidalgo,
G., Fierer, N., and Knight, R. (2010).
Delivery mode shapes the acqui-
sition and structure of the ini-
tial microbiota across multiple body
habitats in newborns. Proc. Natl.
Acad. Sci. U.S.A. 107, 11971–11975.
El-Behi, M., Ciric, B., Dai, H., Yan,
Y., Cullimore, M., Safavi, F., Zhang,
G. X., Dittel, B. N., and Rostami,
A. (2011). The encephalitogenicity
of T(H)17 cells is dependent on
IL-1- and IL-23-induced produc-
tion of the cytokine GM-CSF. Nat.
Immunol. 12, 568–575.
Esplugues, E., Huber, S., Gagliani, N.,
Hauser, A. E., Town, T., Wan, Y.
Y., O’Connor, W., Rongvaux, A.,
Van Rooijen, N., Haberman, A. M.,
Iwakura, Y., Kuchroo, V. K., Kolls, J.
K., Bluestone, J. A., Herold, K. C.,
and Flavell, R. A. (2011). Control
of T(H)17 cells occurs in the small
intestine. Nature 475, 514–518.
FAO/WHO. (2002). Guidelines for the
Evaluation of Probiotics in Food.
Available at: http://www.who.int/
foodsafety/publications/fs_manage
ment/probiotics2/en/index.html
Farrell, R. A., Antony, D., Wall, G.
R., Clark, D. A., Fisniku, L., Swan-
ton, J., Khaleeli, Z., Schmierer, K.,
Miller, D. H., and Giovannoni, G.
(2009). Humoral immune response
to EBV in multiple sclerosis is
Frontiers in Microbiology | Cellular and Infection Microbiology September 2011 | Volume 2 | Article 180 | 8
Kosiewicz et al. Gut microbiota and diseases
associated with disease activity on
MRI. Neurology 73, 32–38.
Feleszko, W., Jaworska, J., Rha, R. D.,
Steinhausen, S., Avagyan, A., Jaud-
szus, A., Ahrens, B., Groneberg, D.
A., Wahn, U., and Hamelmann, E.
(2007). Probiotic-induced suppres-
sion of allergic sensitization and
airway inﬂammation is associated
with an increase of T regulatory-
dependent mechanisms in a murine
model of asthma. Clin. Exp. Allergy
37, 498–505.
Feng, T., Wang, L., Schoeb, T. R., Elson,
C. O., and Cong, Y. (2010). Micro-
biota innate stimulation is a prereq-
uisite forT cell spontaneous prolifer-
ation and induction of experimental
colitis. J. Exp. Med. 207, 1321–1332.
Ferlay, J., Autier, P., Boniol, M., Heanue,
M., Colombet, M., and Boyle, P.
(2007). Estimates of the cancer inci-
dence and mortality in Europe in
2006. Ann. Oncol. 18, 581–592.
Filippi, C., and von Herrath, M.
(2005). How viral infections affect
the autoimmune process leading to
type 1 diabetes. Cell. Immunol. 233,
125–132.
Forsythe, P., Inman, M. D., and Bienen-
stock, J. (2007). Oral treatment with
live Lactobacillus reuteri inhibits the
allergic airway response in mice.
Am. J. Respir. Crit. Care Med. 175,
561–569.
Frank, D. N., St Amand, A. L.,
Feldman, R. A., Boedeker, E. C.,
Harpaz, N., and Pace, N. R. (2007).
Molecular-phylogenetic characteri-
zation of microbial community
imbalances in human inﬂammatory
bowel diseases. Proc. Natl. Acad. Sci.
U.S.A. 104, 13780–13785.
Gaboriau-Routhiau, V., Rakotobe, S.,
Lecuyer, E., Mulder, I., Lan, A.,
Bridonneau, C., Rochet, V., Pisi, A.,
De Paepe, M., Brandi, G., Eberl,
G., Snel, J., Kelly, D., and Cerf-
Bensussan, N. (2009). The key role
of segmented ﬁlamentous bacteria
in the coordinatedmaturation of gut
helper T cell responses. Immunity
31, 677–689.
Gilden, D. H. (2005). Infectious causes
of multiple sclerosis. Lancet Neurol.
4, 195–202.
Gnerlich, J. L., Mitchem, J. B.,Weir, J. S.,
Sankpal, N. V., Kashiwagi, H., Belt,
B. A., Porembka, M. R., Herndon,
J. M., Eberlein, T. J., Goedegebu-
ure, P., and Linehan, D. C. (2010).
Induction of Th17 cells in the
tumor microenvironment improves
survival in a murine model of
pancreatic cancer. J. Immunol. 185,
4063–4071.
Goldin, B. R., and Gorbach, S. L.
(1980). Effect of Lactobacillus aci-
dophilus dietary supplements
on 1,2-dimethylhydrazine
dihydrochloride-induced intestinal
cancer in rats. J. Natl. Cancer Inst.
64, 263–265.
Goldin,B. R.,Gualtieri, L. J., andMoore,
R. P. (1996). The effect of Lactobacil-
lus GG on the initiation and pro-
motion of DMH-induced intestinal
tumors in the rat. Nutr. Cancer 25,
197–204.
Hall, J. A., Bouladoux, N., Sun, C. M.,
Wohlfert, E. A., Blank, R. B., Zhu,
Q., Grigg, M. E., Berzofsky, J. A., and
Belkaid,Y. (2008). Commensal DNA
limits regulatory T cell conversion
and is a natural adjuvant of intestinal
immune responses. Immunity 29,
637–649.
Han, G., Wang, R., Chen, G., Wang, J.,
Xu, R., Wang, L., Feng, J., Li, X.,
Guo, R., Fu, L., Shen, B., and Li,
Y. (2010). Interleukin-17-producing
gammadelta+ T cells protect NOD
mice from type 1 diabetes through
a mechanism involving transform-
ing growth factor-beta. Immunology
129, 197–206.
Harmsen, H. J., Wildeboer-Veloo, A. C.,
Raangs, G. C., Wagendorp, A. A.,
Klijn, N., Bindels, J. G., and Welling,
G. W. (2000). Analysis of intestinal
ﬂora development in breast-fed and
formula-fed infants by using mol-
ecular identiﬁcation and detection
methods. J. Pediatr. Gastroenterol.
Nutr. 30, 61–67.
Hill, D. A., Hoffmann, C., Abt, M.
C., Du, Y., Kobuley, D., Kirn, T.
J., Bushman, F. D., and Artis,
D. (2010). Metagenomic analyses
reveal antibiotic-induced temporal
and spatial changes in intestinal
microbiota with associated alter-
ations in immune cell homeostasis.
Mucosal Immunol. 3, 148–158.
Hopkins, M. J., Macfarlane, G. T.,
Furrie, E., Fite, A., and Macfar-
lane, S. (2005). Characterisation of
intestinal bacteria in infant stools
using real-time PCR and northern
hybridisation analyses. FEMSMicro-
biol. Ecol. 54, 77–85.
Hyttinen, V., Kaprio, J., Kinnunen, L.,
Koskenvuo, M., and Tuomilehto, J.
(2003). Genetic liability of type 1
diabetes and the onset age among
22,650 young Finnish twin pairs:
a nationwide follow-up study. Dia-
betes 52, 1052–1055.
Ishikawa, H., Tanaka, K., Maeda, Y.,
Aiba, Y., Hata, A., Tsuji, N. M.,
Koga, Y., and Matsumoto, T. (2008).
Effect of intestinal microbiota on
the induction of regulatory CD25+
CD4+ T cells. Clin. Exp. Immunol.
153, 127–135.
Ivanov, I. I., Atarashi, K., Manel, N.,
Brodie, E. L., Shima, T., Karaoz, U.,
Wei, D., Goldfarb, K. C., Santee, C.
A., Lynch, S. V., Tanoue, T., Imaoka,
A., Itoh, K., Takeda, K., Umesaki,
Y., Honda, K., and Littman, D. R.
(2009). Induction of intestinal Th17
cells by segmented ﬁlamentous bac-
teria. Cell 139, 485–498.
Ivanov, I. I., Frutos Rde, L., Manel, N.,
Yoshinaga, K., Rifkin, D. B., Sartor,
R. B., Finlay, B. B., and Littman,
D. R. (2008). Speciﬁc microbiota
direct the differentiation of IL-
17-producing T-helper cells in the
mucosa of the small intestine. Cell
Host Microbe 4, 337–349.
Jacobs, J. P., Wu, H. J., Benoist, C., and
Mathis, D. (2009). IL-17-producing
T cells can augment autoantibody-
induced arthritis. Proc. Natl. Acad.
Sci. U.S.A. 106, 21789–21794.
Jakobsson, H. E., Jernberg, C., Ander-
sson, A. F., Sjolund-Karlsson, M.,
Jansson, J. K., and Engstrand,
L. (2010). Short-term antibi-
otic treatment has differing
long-term impacts on the
human throat and gut micro-
biome. PLoS ONE 5, e9836. doi:
10.1371/journal.pone.0009836
Jernberg, C., Lofmark, S., Edlund, C.,
and Jansson, J. K. (2007). Long-
term ecological impacts of antibi-
otic administration on the human
intestinal microbiota. ISME J. 1,
56–66.
Kalliomaki, M., Salminen, S.,
Arvilommi, H., Kero, P., Koski-
nen, P., and Isolauri, E. (2001).
Probiotics in primary prevention
of atopic disease: a randomised
placebo-controlled trial. Lancet 357,
1076–1079.
Kalliomaki, M., Salminen, S., Poussa,
T., Arvilommi, H., and Isolauri, E.
(2003). Probiotics and prevention
of atopic disease: 4-year follow-up
of a randomised placebo-controlled
trial. Lancet 361, 1869–1871.
Kampman, E., Goldbohm, R. A., Van
Den Brandt, P. A., and Van’ T Veer,
P. (1994a). Fermented dairy prod-
ucts, calcium, and colorectal cancer
in The Netherlands Cohort Study.
Cancer Res. 54, 3186–3190.
Kampman, E., Van’ T Veer, P., Hiddink,
G. J., Van Aken-Schneijder, P., Kok,
F. J., and Hermus, R. J. (1994b).
Fermented dairy products, dietary
calcium and colon cancer: a case-
control study in The Netherlands.
Int. J. Cancer 59, 170–176.
Karimi, K., Inman, M. D., Bienenstock,
J., and Forsythe, P. (2009). Lacto-
bacillus reuteri-induced regulatory T
cells protect against an allergic air-
way response in mice. Am. J. Respir.
Crit. Care Med. 179, 186–193.
Kato, I., Endo-Tanaka, K., and
Yokokura, T. (1998). Suppressive
effects of the oral administration
of Lactobacillus casei on type II
collagen-induced arthritis in DBA/1
mice. Life Sci. 63, 635–644.
Kearney, J., Giovannucci, E., Rimm, E.
B., Ascherio, A., Stampfer, M. J.,
Colditz, G. A., Wing, A., Kampman,
E., and Willett, W. C. (1996). Cal-
cium, vitamin D, and dairy foods
and the occurrence of colon can-
cer in men. Am. J. Epidemiol. 143,
907–917.
Kirjavainen, P. V., Apostolou, E., Arvola,
T., Salminen, S. J., Gibson, G. R.,
and Isolauri, E. (2001). Character-
izing the composition of intestinal
microﬂora as a prospective treat-
ment target in infant allergic disease.
FEMS Immunol. Med. Microbiol. 32,
1–7.
Kirjavainen, P. V., Apostolou, E., Salmi-
nen, S. J., and Isolauri, E. (1999).
New aspects of probiotics – a novel
approach in the management of
food allergy. Allergy 54, 909–915.
Klaasen, H. L., Koopman, J. P., Van
Den Brink, M. E., Bakker, M. H.,
Poelma, F. G., and Beynen, A. C.
(1993a). Intestinal, segmented, ﬁla-
mentous bacteria in a wide range
of vertebrate species. Lab. Anim. 27,
141–150.
Klaasen, H. L., Van Der Heijden, P. J.,
Stok, W., Poelma, F. G., Koopman,
J. P., Van Den Brink, M. E., Bakker,
M. H., Eling, W. M., and Beynen,
A. C. (1993b). Apathogenic, intesti-
nal, segmented, ﬁlamentous bacte-
ria stimulate the mucosal immune
system of mice. Infect. Immun. 61,
303–306.
Koenig, J. E., Spor, A., Scalfone, N.,
Fricker,A. D., Stombaugh, J., Knight,
R., Angenent, L. T., and Ley, R.
E. (2011). Succession of micro-
bial consortia in the developing
infant gut microbiome. Proc. Natl.
Acad. Sci. U.S.A. 108(Suppl. 1),
4578–4585.
Kriegel, M. A., Seﬁk, E., Hill, J.
A., Wu, H. J., Benoist, C., and
Mathis, D. (2011). Naturally trans-
mitted segmented ﬁlamentous bac-
teria segregate with diabetes pro-
tection in nonobese diabetic mice.
Proc. Natl. Acad. Sci. U.S.A. 108,
11548–11553.
Kryczek, I., Banerjee, M., Cheng, P.,
Vatan, L., Szeliga, W., Wei, S.,
Huang, E., Finlayson, E., Simeone,
D.,Welling,T.H.,Chang,A.,Coukos,
G., Liu, R., and Zou, W. (2009a).
Phenotype, distribution, generation,
and functional and clinical rele-
vance of Th17 cells in the human
tumor environments. Blood 114,
1141–1149.
Kryczek, I., Wei, S., Szeliga, W., Vatan,
L., and Zou, W. (2009b). Endoge-
nous IL-17 contributes to reduced
www.frontiersin.org September 2011 | Volume 2 | Article 180 | 9
Kosiewicz et al. Gut microbiota and diseases
tumor growth and metastasis. Blood
114, 357–359.
Laan, M., Cui, Z. H., Hoshino, H., Lot-
vall, J., Sjostrand, M., Gruenert, D.
C., Skoogh, B. E., and Linden, A.
(1999). Neutrophil recruitment by
human IL-17 via C-X-C chemokine
release in the airways. J. Immunol.
162, 2347–2352.
Laan, M., Prause, O., Miyamoto, M.,
Sjostrand, M., Hytonen, A. M.,
Kaneko, T., Lotvall, J., and Linden,
A. (2003). A role of GM-CSF in the
accumulation of neutrophils in the
airways caused by IL-17 and TNF-
alpha. Eur. Respir. J. 21, 387–393.
Lavasani, S., Dzhambazov, B., Nouri,
M., Fak, F., Buske, S., Molin, G.,
Thorlacius, H., Alenfall, J., Jepps-
son, B., and Westrom, B. (2010).
A novel probiotic mixture exerts
a therapeutic effect on experimen-
tal autoimmune encephalomyelitis
mediated by IL-10 producing regu-
latory T cells. PLoS ONE 5, e9009.
doi: 10.1371/journal.pone.0009009
Lee, Y. K., Menezes, J. S., Umesaki,
Y., and Mazmanian, S. K. (2011).
Proinﬂammatory T-cell responses to
gut microbiota promote experimen-
tal autoimmune encephalomyelitis.
Proc. Natl. Acad. Sci. U.S.A.
108(Suppl. 1), 4615–4622.
Ley, R. E., Hamady, M., Lozupone,
C., Turnbaugh, P. J., Ramey, R. R.,
Bircher, J. S., Schlegel, M. L., Tucker,
T. A., Schrenzel, M. D., Knight, R.,
and Gordon, J. I. (2008). Evolution
of mammals and their gut microbes.
Science 320, 1647–1651.
Livingston, M., Loach, D., Wilson,
M., Tannock, G. W., and Baird,
M. (2010). Gut commensal Lacto-
bacillus reuteri 100-23 stimulates
an immunoregulatory response.
Immunol. Cell Biol. 88, 99–102.
Lodinova-Zadnikova, R., Cukrowska,
B., and Tlaskalova-Hogenova, H.
(2003). Oral administration of pro-
biotic Escherichia coli after birth
reduces frequency of allergies and
repeated infections later in life (after
10 and 20 years). Int. Arch. Allergy
Immunol. 131, 209–211.
Lubberts, E., Koenders, M. I., Oppers-
Walgreen, B., Van Den Bersselaar,
L., Coenen-De Roo, C. J., Joosten,
L. A., and Van Den Berg, W. B.
(2004). Treatment with a neutraliz-
ing anti-murine interleukin-17 anti-
body after the onset of collagen-
induced arthritis reduces joint
inﬂammation, cartilage destruction,
and bone erosion. Arthritis Rheum.
50, 650–659.
Lyons, A., O’Mahony, D., O’Brien, F.,
Macsharry, J., Sheil, B., Ceddia, M.,
Russell, W. M., Forsythe, P., Bienen-
stock, J., Kiely, B., Shanahan, F.,
and O’Mahony, L. (2010). Bacterial
strain-speciﬁc induction of Foxp3+
T regulatory cells is protective in
murine allergy models. Clin. Exp.
Allergy 40, 811–819.
Macpherson, A. J., and Harris, N. L.
(2004). Interactions between com-
mensal intestinal bacteria and the
immune system. Nat. Rev. Immunol.
4, 478–485.
Majamaa, H., and Isolauri, E. (1997).
Probiotics: a novel approach in
the management of food allergy. J.
Allergy Clin. Immunol. 99, 179–185.
Malhotra, S. L. (1977). Dietary factors
in a study of cancer colon from can-
cer registry, with special reference to
the role of saliva,milk and fermented
milk products and vegetable ﬁbre.
Med. Hypotheses 3, 122–126.
Mandar, R., and Mikelsaar, M. (1996).
Transmission of mother’smicroﬂora
to the newborn at birth. Biol.
Neonate 69, 30–35.
Manirarora, J. N., Parnell, S. A., Hu, Y.-
H., Kosiewicz, M. M., and Alard, P.
(2011). NOD dendritic cells stimu-
lated with lactobacilli preferentially
produce IL-10 versus IL-12 and
decrease diabetes incidence. Clin.
Dev. Immunol. 2011, 630187.
Mannino, D. M., Homa, D. M., Per-
towski, C. A., Ashizawa, A., Nixon,
L. L., Johnson, C. A., Ball, L. B., Jack,
E., and Kang, D. S. (1998). Surveil-
lance for asthma – United States,
1960–1995. MMWR CDC Surveill.
Summ. 47, 1–27.
Martin-Orozco, N., Chung, Y., Chang,
S. H., Wang, Y. H., and Dong, C.
(2009). Th17 cells promote pancre-
atic inﬂammation but only induce
diabetes efﬁciently in lymphopenic
hosts after conversion into Th1 cells.
Eur. J. Immunol. 39, 216–224.
Matsuzaki, T., Nagata, Y., Kado, S.,
Uchida, K., Kato, I., Hashimoto, S.,
and Yokokura, T. (1997). Prevention
of onset in an insulin-dependent
diabetes mellitus model, NOD mice,
by oral feeding of Lactobacillus casei.
APMIS 105, 643–649.
Mazmanian, S. K., Liu, C. H., Tziana-
bos, A. O., and Kasper, D. L. (2005).
An immunomodulatorymolecule of
symbiotic bacteria directs matura-
tion of the host immune system. Cell
122, 107–118.
Mazmanian, S. K., Round, J. L., and
Kasper, D. L. (2008). A microbial
symbiosis factor prevents intestinal
inﬂammatory disease. Nature 453,
620–625.
Muranski, P., Boni, A., Antony, P. A.,
Cassard, L., Irvine, K. R., Kaiser,
A., Paulos, C. M., Palmer, D. C.,
Touloukian, C. E., Ptak, K., Gat-
tinoni, L., Wrzesinski, C., Hin-
richs, C. S., Kerstann, K. W.,
Feigenbaum, L., Chan, C. C., and
Restifo, N. P. (2008). Tumor-speciﬁc
Th17-polarized cells eradicate large
established melanoma. Blood 112,
362–373.
Nikoopour, E., Schwartz, J. A.,Huszarik,
K., Sandrock, C., Krougly, O., Lee-
Chan, E., and Singh, B. (2010). Th17
polarized cells from nonobese dia-
betic mice following mycobacter-
ial adjuvant immunotherapy delay
type 1 diabetes. J. Immunol. 184,
4779–4788.
Noverr, M. C., and Huffnagle, G. B.
(2005). The “microﬂora hypothesis”
of allergic diseases. Clin. Exp. Allergy
35, 1511–1520.
Noverr, M. C., Noggle, R. M., Toews,
G. B., and Huffnagle, G. B. (2004).
Role of antibiotics and fungalmicro-
biota in driving pulmonary aller-
gic responses. Infect. Immun. 72,
4996–5003.
Ochoa-Reparaz, J., Mielcarz, D. W.,
Ditrio, L. E., Burroughs, A. R.,
Foureau, D. M., Haque-Begum, S.,
and Kasper, L. H. (2009). Role
of gut commensal microﬂora in
the development of experimental
autoimmune encephalomyelitis. J.
Immunol. 183, 6041–6050.
Ochoa-Reparaz, J., Mielcarz, D. W.,
Wang, Y., Begum-Haque, S., Das-
gupta,S.,Kasper,D. L., andKasper,L.
H. (2010).Apolysaccharide from the
human commensal Bacteroides frag-
ilis protects against CNS demyeli-
nating disease. Mucosal Immunol. 3,
487–495.
Okada, H., Kuhn, C., Feillet, H., and
Bach, J. F. (2010). The “hygiene
hypothesis” for autoimmune and
allergic diseases: an update. Clin.
Exp. Immunol. 160, 1–9.
O’Keefe, S. J., Ou, J., Aufreiter, S.,
O’Connor, D., Sharma, S., Sepul-
veda, J., Fukuwatari, T., Shibata, K.,
and Mawhinney, T. (2009). Products
of the colonic microbiota mediate
the effects of diet on colon cancer
risk. J. Nutr. 139, 2044–2048.
O’Mahony, C., Scully, P., O’Mahony, D.,
Murphy, S., O’Brien, F., Lyons, A.,
Sherlock, G., Macsharry, J., Kiely,
B., Shanahan, F., and O’Mahony,
L. (2008). Commensal-induced reg-
ulatory T cells mediate protec-
tion against pathogen-stimulated
NF-kappaB activation. PLoS Pathog.
4, e1000112. doi: 10.1371/jour-
nal.ppat.1000112
Onderdonk, A. B., Steeves, R. M.,
Cisneros, R. L., and Bronson, R.
T. (1984). Adoptive transfer of
immune enhancement of exper-
imental ulcerative colitis. Infect.
Immun. 46, 64–67.
Oyama, N., Sudo, N., Sogawa, H.,
and Kubo, C. (2001). Antibiotic
use during infancy promotes a
shift in the T(H)1/T(H)2 balance
toward T(H)2-dominant immunity
in mice. J. Allergy Clin. Immunol.
107, 153–159.
Packey, C. D., and Sartor, R. B. (2008).
Interplay of commensal and path-
ogenic bacteria, genetic mutations,
and immunoregulatory defects in
the pathogenesis of inﬂammatory
bowel diseases. J. Intern. Med. 263,
597–606.
Palmer, C., Bik, E. M., Digiulio, D. B.,
Relman, D. A., and Brown, P. O.
(2007). Development of the human
infant intestinal microbiota. PLoS
Biol. 5, e177. doi: 10.1371/jour-
nal.pbio.0050177
Penders, J., Thijs, C., Vink, C., Stelma,
F. F., Snijders, B., Kummeling, I.,Van
Den Brandt, P. A., and Stobberingh,
E. E. (2006). Factors inﬂuencing the
composition of the intestinal micro-
biota in early infancy. Pediatrics 118,
511–521.
Peters, R. K., Pike, M. C., Garabrant, D.,
and Mack, T. M. (1992). Diet and
colon cancer in Los Angeles County,
California. Cancer Causes Control 3,
457–473.
Pineton de Chambrun, G., Colombel,
J. F., Poulain, D., and Darfeuille-
Michaud, A. (2008). Pathogenic
agents in inﬂammatory bowel dis-
eases. Curr. Opin. Gastroenterol. 24,
440–447.
Poole, B. D., Scoﬁeld, R. H.,Harley, J. B.,
and James, J. A. (2006). Epstein-Barr
virus and molecular mimicry in sys-
temic lupus erythematosus. Autoim-
munity 39, 63–70.
Pool-Zobel, B. L., Neudecker, C.,
Domizlaff, I., Ji, S., Schillinger,
U., Rumney, C., Moretti, M.,
Vilarini, I., Scassellati-Sforzolini,
R., and Rowland, I. (1996).
Lactobacillus- and Biﬁdobacterium-
mediated antigenotoxicity in the
colon of rats. Nutr. Cancer 26,
365–380.
Rabizadeh, S., Rhee, K. J., Wu, S.,
Huso, D., Gan, C. M., Golub, J.
E., Wu, X., Zhang, M., and Sears,
C. L. (2007). Enterotoxigenic Bac-
teroides fragilis: a potential instigator
of colitis. Inﬂamm. Bowel Dis. 13,
1475–1483.
Rajilic-Stojanovic, M., Smidt, H., and
De Vos, W. M. (2007). Diver-
sity of the human gastrointestinal
tract microbiota revisited. Environ.
Microbiol. 9, 2125–2136.
Rhee, K. J., Wu, S., Wu, X., Huso,
D. L., Karim, B., Franco, A. A.,
Rabizadeh, S., Golub, J. E., Mathews,
L. E., Shin, J., Sartor, R. B., Golen-
bock, D., Hamad, A. R., Gan, C. M.,
Housseau, F., and Sears, C. L. (2009).
Induction of persistent colitis by a
human commensal, enterotoxigenic
Bacteroides fragilis, in wild-type
C57BL/6 mice. Infect. Immun. 77,
1708–1718.
Frontiers in Microbiology | Cellular and Infection Microbiology September 2011 | Volume 2 | Article 180 | 10
Kosiewicz et al. Gut microbiota and diseases
Rosenfeldt, V., Benfeldt, E., Nielsen, S.
D., Michaelsen, K. F., Jeppesen, D.
L., Valerius, N. H., and Paerregaard,
A. (2003). Effect of probiotic Lac-
tobacillus strains in children with
atopic dermatitis. J. Allergy Clin.
Immunol. 111, 389–395.
Round, J. L., Lee, S. M., Li, J., Tran,
G., Jabri, B., Chatila, T. A., and
Mazmanian, S. K. (2011). The Toll-
like receptor 2 pathway establishes
colonization by a commensal of
the human microbiota. Science 332,
974–977.
Round, J. L., and Mazmanian, S. K.
(2009). The gut microbiota shapes
intestinal immune responses dur-
ing health and disease. Nat. Rev.
Immunol. 9, 313–323.
Rowland, I. R., Rumney, C. J., Coutts,
J. T., and Lievense, L. C. (1998).
Effect of Biﬁdobacterium longum
and inulin on gut bacterial metab-
olism and carcinogen-induced aber-
rant crypt foci in rats. Carcinogenesis
19, 281–285.
Sanderson, J. D., and Hermon-Taylor, J.
(1992).Mycobacterial diseases of the
gut: some impact from molecular
biology. Gut 33, 145–147.
Sfanos, K. S., Bruno, T. C., Maris, C.
H., Xu, L., Thoburn, C. J., Demarzo,
A. M., Meeker, A. K., Isaacs, W. B.,
and Drake, C. G. (2008). Pheno-
typic analysis of prostate-inﬁltrating
lymphocytes reveals TH17 and Treg
skewing. Clin. Cancer Res. 14,
3254–3261.
Silva, W. A. Jr., Covas, D. T., Panepucci,
R. A., Proto-Siqueira, R., Siuﬁ, J. L.,
Zanette, D. L., Santos, A. R., and
Zago, M. A. (2003). The proﬁle of
gene expression of human marrow
mesenchymal stem cells. Stem Cells
21, 661–669.
Snel, J., Heinen, P. P., Blok, H. J., Car-
man, R. J., Duncan, A. J., Allen, P.
C., and Collins, M. D. (1995). Com-
parison of 16S rRNA sequences of
segmented ﬁlamentous bacteria iso-
lated from mice, rats, and chick-
ens and proposal of “Candidatus
arthromitus.” Int. J. Syst. Bacteriol.
45, 780–782.
So, J. S., Kwon, H. K., Lee, C. G., Yi, H.
J., Park, J. A., Lim, S. Y., Hwang, K.
C., Jeon, Y. H., and Im, S. H. (2008).
Lactobacillus casei suppresses experi-
mental arthritis by down-regulating
T helper 1 effector functions. Mol.
Immunol. 45, 2690–2699.
Sokol, H., Pigneur, B., Watterlot, L.,
Lakhdari, O., Bermudez-Humaran,
L. G., Gratadoux, J. J., Blugeon, S.,
Bridonneau, C., Furet, J. P., Cor-
thier, G., Grangette, C., Vasquez, N.,
Pochart,P.,Trugnan,G.,Thomas,G.,
Blottiere, H. M., Dore, J., Marteau,
P., Seksik, P., and Langella, P. (2008).
Faecalibacterium prausnitzii is an
anti-inﬂammatory commensal bac-
terium identiﬁed by gut microbiota
analysis of Crohn disease patients.
Proc. Natl. Acad. Sci. U.S.A. 105,
16731–16736.
Sokol,H.,Seksik,P.,Furet, J. P.,Firmesse,
O.,Nion-Larmurier, I., Beaugerie, L.,
Cosnes, J., Corthier, G., Marteau, P.,
and Dore, J. (2009). Low counts of
Faecalibacterium prausnitzii in coli-
tis microbiota. Inﬂamm. Bowel Dis.
15, 1183–1189.
Sood, A., Midha, V., Makharia, G. K.,
Ahuja, V., Singal, D., Goswami, P.,
and Tandon, R. K. (2009). The pro-
biotic preparation, VSL#3 induces
remission in patients with mild-
to-moderately active ulcerative col-
itis. Clin. Gastroenterol. Hepatol. 7,
1202–1209, 1209 e1201.
Stepankova, R., Powrie, F., Kofronova,
O., Kozakova, H., Hudcovic, T.,
Hrncir, T., Uhlig, H., Read, S.,
Rehakova, Z., Benada,O.,Heczko, P.,
Strus, M., Bland, P., and Tlaskalova-
Hogenova, H. (2007). Segmented
ﬁlamentous bacteria in a deﬁned
bacterial cocktail induce intestinal
inﬂammation in SCID mice recon-
stituted with CD45RBhigh CD4+
T cells. Inﬂamm. Bowel Dis. 13,
1202–1211.
Stone, M., Fortin, P. R., Pacheco-
Tena, C., and Inman, R. D. (2003).
Should tetracycline treatment be
used more extensively for rheuma-
toid arthritis? Metaanalysis demon-
strates clinical beneﬁt with reduc-
tion in disease activity. J. Rheumatol.
30, 2112–2122.
Talham, G. L., Jiang, H. Q., Bos, N.
A., and Cebra, J. J. (1999). Seg-
mented ﬁlamentous bacteria are
potent stimuli of a physiologically
normal state of the murine gut
mucosal immune system. Infect.
Immun. 67, 1992–2000.
Toivanen, P. (2003). Normal intesti-
nal microbiota in the aetiopatho-
genesis of rheumatoid arthritis.Ann.
Rheum. Dis. 62, 807–811.
Turnbaugh, P. J., Ridaura, V. K., Faith,
J. J., Rey, F. E., Knight, R., and Gor-
don, J. I. (2009). The effect of diet
on the human gut microbiome: a
metagenomic analysis in humanized
gnotobiotic mice. Sci. Transl. Med. 1,
6ra14.
Tursi, A., Brandimarte, G., Papa, A.,
Giglio,A., Elisei,W.,Giorgetti,G.M.,
Forti, G., Morini, S., Hassan, C., Pis-
toia, M. A., Modeo, M. E., Rodino,
S., D’Amico, T., Sebkova, L., Sacca,
N., Di Giulio, E., Luzza, F., Imeneo,
M., Larussa, T., Di Rosa, S., Annese,
V., Danese, S., and Gasbarrini, A.
(2010). Treatment of relapsing mild-
to-moderate ulcerative colitis with
the probiotic VSL#3 as adjunc-
tive to a standard pharmaceutical
treatment: a double-blind, random-
ized, placebo-controlled study. Am.
J. Gastroenterol. 105, 2218–2227.
Umesaki, Y., Okada, Y., Matsumoto,
S., Imaoka, A., and Setoyama, H.
(1995). Segmented ﬁlamentous bac-
teria are indigenous intestinal bacte-
ria that activate intraepithelial lym-
phocytes and induce MHC class II
molecules and fucosyl asialo GM1
glycolipids on the small intesti-
nal epithelial cells in the ex-germ-
free mouse. Microbiol. Immunol. 39,
555–562.
Uronis, J. M., Muhlbauer, M., Herfarth,
H. H., Rubinas, T. C., Jones, G. S.,
and Jobin, C. (2009). Modulation
of the intestinal microbiota alters
colitis-associated colorectal cancer
susceptibility. PLoS ONE 4, e6026.
doi: 10.1371/journal.pone.0006026
Vaahtovuo, J., Munukka, E., Korkea-
maki,M.,Luukkainen,R., andToiva-
nen, P. (2008). Fecal microbiota
in early rheumatoid arthritis. J.
Rheumatol. 35, 1500–1505.
Veiga, P., Gallini, C. A., Beal, C.,
Michaud, M., Delaney, M. L.,
Dubois, A., Khlebnikov, A.,Van Hyl-
ckama Vlieg, J. E., Punit, S., Glick-
man, J. N., Onderdonk, A., Glim-
cher, L. H., and Garrett,W. S. (2010).
Biﬁdobacteriumanimalis subsp. Lac-
tis fermented milk product reduces
inﬂammation by altering a niche
for colitogenic microbes. Proc. Natl.
Acad. Sci. U.S.A. 107, 18132–18137.
Viljanen, M., Savilahti, E., Haahtela, T.,
Juntunen-Backman, K., Korpela, R.,
Poussa, T., Tuure, T., and Kuitunen,
M. (2005). Probiotics in the treat-
ment of atopic eczema/dermatitis
syndrome in infants: a double-blind
placebo-controlled trial. Allergy 60,
494–500.
Vliagoftis, H., Kouranos, V. D., Betsi, G.
I., and Falagas, M. E. (2008). Pro-
biotics for the treatment of aller-
gic rhinitis and asthma: systematic
review of randomized controlled tri-
als. Ann. Allergy Asthma Immunol.
101, 570–579.
Ward, J. M., Anver, M. R., Haines, D. C.,
Melhorn, J. M., Gorelick, P., Yan, L.,
and Fox, J. G. (1996). Inﬂammatory
large bowel disease in immunode-
ﬁcient mice naturally infected with
Helicobacter hepaticus. Lab. Anim.
Sci. 46, 15–20.
Wen, L., Ley, R. E., Volchkov, P. Y.,
Stranges, P. B., Avanesyan, L., Stone-
braker, A. C., Hu, C., Wong, F.
S., Szot, G. L., Bluestone, J. A.,
Gordon, J. I., and Chervonsky, A.
V. (2008). Innate immunity and
intestinal microbiota in the develop-
ment of type 1 diabetes. Nature 455,
1109–1113.
Wu, H. J., Ivanov, Ii, Darce, J., Hattori,
K., Shima, T., Umesaki, Y., Littman,
D. R., Benoist, C., and Mathis, D.
(2010). Gut-residing segmented ﬁla-
mentous bacteria drive autoimmune
arthritis via T helper 17 cells. Immu-
nity 32, 815–827.
Wu, S., Rhee, K. J., Albesiano, E.,
Rabizadeh, S., Wu, X., Yen, H. R.,
Huso, D. L., Brancati, F. L., Wick,
E., Mcallister, F., Housseau, F., Par-
doll, D. M., and Sears, C. L. (2009).
A human colonic commensal pro-
motes colon tumorigenesis via acti-
vation of T helper type 17 T cell
responses. Nat. Med. 15, 1016–1022.
Yao, Z., Fanslow, W. C., Seldin, M.
F., Rousseau, A. M., Painter, S. L.,
Comeau, M. R., Cohen, J. I., and
Spriggs, M. K. (1995). Herpesvirus
Saimiri encodes a new cytokine, IL-
17, which binds to a novel cytokine
receptor. Immunity 3, 811–821.
Yoshioka, H., Iseki, K., and Fujita, K.
(1983). Development and differ-
ences of intestinal ﬂora in the neona-
tal period in breast-fed and bottle-
fed infants. Pediatrics 72, 317–321.
Zandman-Goddard, G., and Shoen-
feld, Y. (2005). Infections and SLE.
Autoimmunity 38, 473–485.
Zhang, B., Rong, G.,Wei,H., Zhang,M.,
Bi, J., Ma, L., Xue, X., Wei, G., Liu,
X., and Fang, G. (2008). The preva-
lence of Th17 cells in patients with
gastric cancer.Biochem. Biophys. Res.
Commun. 374, 533–537.
Zhang, L. L., Chen, X., Zheng, P. Y., Luo,
Y., Lu, G. F., Liu, Z. Q., Huang, H.,
and Yang, P. C. (2010). Oral Biﬁ-
dobacterium modulates intestinal
immune inﬂammation in mice with
food allergy. J. Gastroenterol. Hepa-
tol. 25, 928–934.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 06 May 2011; accepted: 16
August 2011; published online: 05 Sep-
tember 2011.
Citation: Kosiewicz MM, Zirnheld AL
and Alard P (2011) Gut microbiota,
immunity, and disease: a complex rela-
tionship. Front. Microbio. 2:180. doi:
10.3389/fmicb.2011.00180
This article was submitted to Frontiers
in Cellular and Infection Microbiology, a
specialty of Frontiers in Microbiology.
Copyright © 2011 Kosiewicz, Zirnheld
and Alard. This is an open-access arti-
cle subject to a non-exclusive license
between the authors and Frontiers Media
SA, which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and other Frontiers conditions are
complied with.
www.frontiersin.org September 2011 | Volume 2 | Article 180 | 11
